J Korean Rheum Assoc.  2010 Jun;17(2):162-167. 10.4078/jkra.2010.17.2.162.

Adherence to Uric Acid Lowering Agent of Gouty Patients

• Son KM
• Seo YI
• Kim IJ
• Bae YD
• Jung YO
• Cha MJ
• Kim HA

• KMID: 2201961
• DOI: http://doi.org/10.4078/jkra.2010.17.2.162

Abstract

OBJECTIVE
Gout is crystal-induced arthritis with hyperuricemia. Uric acid lowering agent (UALA) is the maintenance drug of its treatment. Drug adherence is an important factor that influences treatment outcome. The purpose this study was to examine the drug adherence to UALA of 303 gouty patients and to analyze the factors associated with compliance.
METHODS
We retrospectively assessed adherence to UALA in 303 patients who visited three hospitals affiliated with Hallym University. Patients were diagnosed as gout and used UALA with at least 6 month follow-up. Two adherence measures were calculated, the percentage of days covered (PDC) and the time until an extended break (at least 60 days) in treatment. A PDC <70% was considered poor adherence and factors associated with poor adherence were examined.
RESULTS
Among the 303 patients, 283 (93.4%) were male. Mean age was 55.4+/-13.7 years. Comorbidities included hypertension in 117 (38.6%), diabetic mellitus in 108 (35.6%), angina in 107 (35.3%), myocardial infarction in 108 (35.6%), and heart failure in 113 (37.3%). The mean PDC was 65.8% with 63.4% of patients considered poorly compliant over the study period. Mean treatment duration before an extended break occurred was 203.5 days. Factors associated with good adherence included hypertension and prescription from rheumatologist.
CONCLUSION
In our study, adherence to UALA in gouty patient was poor. Understanding the factors associated with adherence to UALA and proper education of gouty patients to improve drug adherence are needed.

Keyword

Gout; Uric acid; Adherence

MeSH Terms

Arthritis
Comorbidity
Compliance
Follow-Up Studies
Gout
Heart Failure
Humans
Hypertension
Hyperuricemia
Male
Myocardial Infarction
Prescriptions
Retrospective Studies
Treatment Outcome
Uric Acid
Uric Acid

Reference

1). Riedel AA., Nelson M., Joseph-Ridge N., Wallace K., MacDonald P., Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004. 31:1575–81.

2). Solomon DH., Avorn J., Levin R., Brookhart MA. Uric aid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008. 67:609–13.

3). Harrold LR., Andrade SE., Briesacher BA., Raebel MA., Fouayzi H., Yood RA, et al. Adherence with uratelowering therapies for the treatment of gout. Arthritis Res Ther. 2009. 11:R46.

4). Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit. 2000. ;5 Suppl. 3:31. S.

5). Cantrell CR., Eaddy MT., Shah MB., Regan TS., Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006. 44:300–3.

6). Benner JS., Glynn RJ., Mogun H., Neumann PJ., Weinstein MC., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002. 288:455–61.

7). Park CY., Yim J., Kang IO., Im J. The health behavior and medication compliance of patients with hypertension and diabetes mellitus. Health Insurance Forum. 2007. 6:111–21.

8). Kim GY., Park JB., Kim BW. Short-term glycemic control and the related factor in associated with compliance in diabetic patient. J Prev Med Public Health. 2000. 33:347–63.

9). Harrold LR., Andrade SE., Briesacher B., Raebel MA., Fouayzi H., Yood RA, et al. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010. 123:54–9.